Literature DB >> 31767364

Outcome of delayed versus timely esophagectomy after chemoradiation for esophageal adenocarcinoma.

Nick C Levinsky1, Koffi Wima1, Mackenzie C Morris1, Syed A Ahmad2, Shimul A Shah1, Sandra L Starnes3, Robert M Van Haren4.   

Abstract

BACKGROUND: Salvage and delayed esophagectomy after chemoradiation therapy (CRT) have been associated with increased morbidity and mortality, but recent series have shown similar outcomes compared to timely esophagectomy. We aim to evaluate outcomes for delayed and salvage esophagectomy for esophageal adenocarcinoma utilizing a large national database.
METHODS: The National Cancer Database for 2004 to 2014 was queried for patients with clinical stage II or III esophageal adenocarcinoma who underwent preoperative CRT and esophagectomy. Patients who underwent surgery <90 days after CRT were defined as the timely esophagectomy group (n = 7822), and those who underwent surgery ≥90 days after CRT were defined as the delayed esophagectomy group (n = 667).
RESULTS: A total of 8489 patients met our inclusion criteria. The median post-CRT interval was 49 days (range, 40-61 days) for the timely esophagectomy group and 109 days (range, 97-132 days) for the delayed esophagectomy group. The delayed group was more likely to be of black race (2.3% vs 1.2%; P < .01) and more likely to have Medicare (47.9% vs 39.8%; P < .001). There were no significant between-group differences in chemotherapy regimens (P = .17), radiation dose (P = .18), or surgical approach (P = .48). The delayed esophagectomy group had higher rates of pathological complete response (22.2% vs 18.6%; P = .043) and 90-day postoperative mortality (10.4% vs 7.8%; P < .01). On multivariate analysis, delayed esophagectomy was not independently associated with decreased overall survival.
CONCLUSIONS: In this large retrospective database study, despite increased perioperative mortality, delayed and salvage esophagectomy for adenocarcinoma appear to have similar long-term survival as timely esophagectomy. Delayed and salvage esophagectomy may be offered to patients who do not receive timely esophagectomy after CRT.
Copyright © 2019 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chemoradiation; esophageal cancer; esophagectomy

Mesh:

Year:  2019        PMID: 31767364     DOI: 10.1016/j.jtcvs.2019.09.169

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  It's not always too late: a case for minimally invasive salvage esophagectomy.

Authors:  Ryan C Broderick; Arielle M Lee; Rachel R Blitzer; Beiqun Zhao; Jenny Lam; Joslin N Cheverie; Bryan J Sandler; Garth R Jacobsen; Mark W Onaitis; Kaitlyn J Kelly; Michael Bouvet; Santiago Horgan
Journal:  Surg Endosc       Date:  2020-09-17       Impact factor: 4.584

2.  COVID-19 Guidance for Triage of Operations for Thoracic Malignancies: A Consensus Statement From Thoracic Surgery Outcomes Research Network.

Authors:  Mara Antonoff; Leah Backhus; Daniel J Boffa; Stephen R Broderick; Lisa M Brown; Phillip Carrott; James M Clark; David Cooke; Elizabeth David; Matt Facktor; Farhood Farjah; Eric Grogan; James Isbell; David R Jones; Biniam Kidane; Anthony W Kim; Shaf Keshavjee; Seth Krantz; Natalie Lui; Linda Martin; Robert A Meguid; Shari L Meyerson; Tim Mullett; Heidi Nelson; David D Odell; Joseph D Phillips; Varun Puri; Valerie Rusch; Lawrence Shulman; Thomas K Varghese; Elliot Wakeam; Douglas E Wood
Journal:  Ann Thorac Surg       Date:  2020-04-09       Impact factor: 4.330

3.  COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network.

Authors:  Mara Antonoff; Leah Backhus; Daniel J Boffa; Stephen R Broderick; Lisa M Brown; Phillip Carrott; James M Clark; David Cooke; Elizabeth David; Matt Facktor; Farhood Farjah; Eric Grogan; James Isbell; David R Jones; Biniam Kidane; Anthony W Kim; Shaf Keshavjee; Seth Krantz; Natalie Lui; Linda Martin; Robert A Meguid; Shari L Meyerson; Tim Mullett; Heidi Nelson; David D Odell; Joseph D Phillips; Varun Puri; Valerie Rusch; Lawrence Shulman; Thomas K Varghese; Elliot Wakeam; Douglas E Wood
Journal:  J Thorac Cardiovasc Surg       Date:  2020-04-09       Impact factor: 5.209

Review 4.  The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer-A Review.

Authors:  Dan Han; Baosheng Li; Qian Zhao; Hongfu Sun; Jinling Dong; Shaoyu Hao; Wei Huang
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

5.  [Surgical treatment of esophageal cancer-Indicators for quality in diagnostics and treatment].

Authors:  Jens Hoeppner; Patrick Sven Plum; Heinz Buhr; Ines Gockel; Dietmar Lorenz; Michael Ghadimi; Christiane Bruns
Journal:  Chirurg       Date:  2021-04       Impact factor: 0.955

Review 6.  A narrative review of socioeconomic disparities in the treatment of esophageal cancer.

Authors:  Aaron M Delman; Allison M Ammann; Kevin M Turner; Dennis M Vaysburg; Robert M Van Haren
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.